Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma

Immune checkpoint inhibitors have limited efficacy in the treatment of pancreatic ductal adenocarcinoma (PDAC). We investigated prognostic markers for nivolumab-based therapy in advanced or recurrent PDAC. Consecutive patients receiving nivolumab-based therapy at our institution between 2015 and 202...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shih-Hung, Lu, Li-Chun, Kao, Hsiang-Fong, Chen, Bang-Bin, Kuo, Ting-Chun, Kuo, Sung-Hsin, Tien, Yu-Wen, Bai, Li-Yuan, Cheng, Ann-Lii, Yeh, Kun-Huei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477954/
https://www.ncbi.nlm.nih.gov/pubmed/34595057
http://dx.doi.org/10.1080/2162402X.2021.1973710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477954/
https://www.ncbi.nlm.nih.gov/pubmed/34595057
http://dx.doi.org/10.1080/2162402X.2021.1973710

Ejemplares similares